This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amedisys Buys 6 Home Health, Hospice Care Centers from Tenet
by Zacks Equity Research
Amedisys Inc. (AMED), a household name in home health and hospice services space, recently signed an exclusive agreement with Tenet Healthcare Corporation (THC).
Penumbra (PEN) Q4 Loss Narrower than Expected, Sales Top
by Zacks Equity Research
Penumbra, Inc. (PEN), that went public in Sep 2015, reported fourth-quarter 2016 loss of 8 cents per share, down from earnings of 5 cents per share year over year.
Mead Johnson Acquires Bega's Strategic Capabilities Business
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) recently inked an agreement with Bega Cheese Limited to acquire the latter's spray drying and finishing capabilities business in Australia.
Amedisys (AMED) Earnings Top Q4 Estimates, Revenues Lag
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 44 cents per share in the fourth quarter of 2016, up 10% year over year.
Why Is Cardiovascular Systems (CSII) Up 11.1% Since the Last Earnings Report?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Presents 5-Year Cost Data of CRT Devices
by Zacks Equity Research
Medtronic plc (MDT) recently presented a five-year data report on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) division.
VWR Corporation (VWR) Tops Earnings in Q4; View Dull
by Zacks Equity Research
VWR Corporation (VWR) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 45 cents, reflecting a 4.3% decline from the year-ago quarter.
Integra (IART) Posts In-Line Q4 Earnings, Issues 2017 View
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 52 cents in the fourth quarter of 2016, up 18% from the year-ago adjusted number.
Medtronic Poised on Strong Fundamentals Despite Several Woes
by Zacks Equity Research
On Feb 23, we issued an updated research report on medical device major, Medtronic plc (MDT).
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise
by Zacks Equity Research
On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Align Expands Internationally with Dental Couture Buyout
by Zacks Equity Research
Align Technology (ALGN) has recently announced the acquisition of Dubai, UAE and Nicosia, Cyprus-based distributor, G.L. Dental Couture Limited.
Henry Schein Inks Agreement for Rijuven's CardioSleeve
by Zacks Equity Research
Henry Schein, Inc. (HSIC) recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. to sell the latter's CardioSleeve device
Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.
Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4
by Zacks Equity Research
Ecolab Inc. (ECL) reported fourth-quarter 2016 adjusted earnings of $1.25 per share, which missed the Zacks Consensus Estimate of $1.27.
Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View
by Zacks Equity Research
Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.
Henry Schein to Acquire SAS to Strengthen Dental Offerings
by Zacks Equity Research
Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).
GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y
by Zacks Equity Research
GNC Holdings Inc. (GNC) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 37 cents, down 88.1% and also missed the Zacks Consensus Estimate by 81.1%.
Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.
LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH) or LabCorp reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.15, up 8.6% from the year-ago quarter.
Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View
by Zacks Equity Research
Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.
Genomic Health (GHDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.
Medtronic (MDT) Adds New Tools, Expands Coronary Suite
by Zacks Equity Research
Medtronic plc (MDT) recently added DxTerity Diagnostic Angiography Catheter line and several transradial-specific products to its market-leading coronary portfolio.
Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance
by Zacks Equity Research
Bruker Corporation (BRKR) reported fourth quarter 2016 adjusted EPS of 46 cents, up 21.1% year over year and also surpassed the Zacks Consensus Estimate of 37 cents.
Omnicell Partners with DCH Health for Sterile Compounding
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.